comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 01:50:32 - browse：4437

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Sage's campaign to raise awareness of postpartum depression hits a nerve

WSS

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

CDC launches VaccineFinder tool to locate Covid

How to make Best Hospitals ratings actually useful for patients

Why more medical students aren't specializing in primary care

More regulation could be coming for drug ads

Biden praises World Series champion Astros for impact off the field during White House celebration

focus

comprehensive

entertainment

What does generative AI mean for health care? We asked experts

Biden praises World Series champion Astros for impact off the field during White House celebration

Psychedelics group wrestles with new pharma identity

What AAP's gender

Drug repurposing or repositioning? The language matters

In venture capital firm's success, lessons for turning crisis into profit

DIEP, the 'gold standard' of breast reconstruction, is under threat

Diversity in medical illustrations gets boost from Chidiebere Ibe

United colonoscopy coverage change 'may cost lives,' doctors say

Apellis safety probe of eye disease drug centers on injection needle

hotspot

How to make Best Hospitals ratings actually useful for patients

How to make Best Hospitals ratings actually useful for patients

Judge rejects Trump's counterclaim against E. Jean Carroll

Study finds new variant for Parkinson’s in African populations

‘The Bear’ and hospitality in hospitals

Winners, losers from Medicare’s list of drugs subject to price talks

leisure time

focus

hotspot

hotspot